共 50 条
Neuroprotection of retinal ganglion cells in DBA/2J mice with GDNF-loaded biodegradable microspheres
被引:82
|作者:
Ward, M. S.
Khoobehi, A.
Lavik, E. B.
Langer, R.
Young, M. J.
机构:
[1] Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA
[2] MIT, Dept Chem Engn, Cambridge, MA 02139 USA
[3] Yale Univ, Dept Biol Engn, New Haven, CT 06520 USA
关键词:
microsphere;
neuroprotection;
glaucoma;
retina;
D O I:
10.1002/jps.20629
中图分类号:
R914 [药物化学];
学科分类号:
100701 ;
摘要:
This study aims to promote long-term retinal ganglion cell (RGC) survival in a spontaneous glaucoma model by injecting slow-release Poly(DL-lactide-co-glycolide) (PLGA) microspheres containing glial cell line-derived neurotrophic factor (GDNF) into the vitreous. Microspheres (1 mu L) suspended in PBS were injected in ipsilateral eyes while contralateral. eyes served as untreated controls. Mice were injected at 2 months intervals (1-4 injections) depending on the protocol. ELISA assay indicated a cumulative GDNF release of 35.4 ng/mg over 71 days. The release was nonlinear with an initial burst of over 50%. Mice displayed a 30% drop in RGC density by 8 months (p = 0.013) and 80% drop by 10 months (p < 0.01). GDNF delivery increased RGC survival in all groups. Mice receiving early treatment showed up to 3.5 times greater RGC density than untreated mice at 15 months survival (p < 0.05). No significant effect was found in sham or lens injury groups. Microsphere-delivered GDNF significantly increases long-term RGC survival in a spontaneous glaucoma model, although the nonlinear release kinetics suggest that burst release may play a role in this rescue. Neuroprotection with slow-release polymers with improved release kinetics should be further studied as a potential therapy for glaucoma and other diseases involving the loss of central nervous system neurons. (c) 2006 Wiley-Liss, Inc. and the American Pharmacists Association.
引用
收藏
页码:558 / 568
页数:11
相关论文